2 results
Approved WMORecruiting
The primary objective is to develop algorithms that define digital biomarkers for disease progression in Progressive Supranuclear Palsy patients. The biomarkers, when developed systematically, can eventually serve as primary or secondary clinical…
Approved WMOPending
Primary Objective• To assess the effect of ALX148 + pembrolizumab + 5FU + platinum on 12-month overall survival (OS) rate and objective response rate (ORR)in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated…